Abstract:Background: Mucosal-associated invariant T cells (MAIT) are unconventional αβT cells with a semi-invariant TCR that recognizes microbially-derived riboflavin metabolites presented by MHC-related protein 1 (MR1). Upon TCR engagement or cytokine stimulation, MAIT cells can rapidly secrete pro-inflammatory cytokines and cytotoxic molecules. The precise role of MAIT cells in the tumor-immune microenvironment remains unclear, as different reports have described them as either beneficial or detrimental to patient prognosis. Considering that MAIT cells constitute a notable proportion (2-4%) of the lung T cell repertoire in both humans and mice, the lung serves as an appropriate setting for ex vivo and in vivo MAIT cell characterization. Objective: To characterize the phenotype of MAIT cells in lung tumor and uninvolved tissue from non-small cell lung cancer (NSCLC) specimens and orthotopic murine models. Results: Surgical resections of primary tumor and normal adjacent tissue from 29 treatment-naïve NSCLC patients were profiled using a comprehensive 31-marker spectral flow cytometry panel. MAIT cells expressing activating and inhibitory receptors including CD69, PD-1, CTLA-4, and CD39, were enriched in tumor tissue. Conversely, cytotoxic MAIT cells expressing granzyme B, granulysin, and CD57, were enriched in normal adjacent tissue. For in vivo studies, lungs of B6-MAITCAST mice, which harbor higher frequencies of MAIT cells compared to conventional mouse strains, were orthotopically injected with CMT167 tumor cells or vehicle control. MAIT cells from lungs injected with CMT167 tumors also expressed higher levels of activating and inhibitory receptors, and decreased levels of granzyme B. Additionally, there was a slight decrease in IFNγ and IL-17A production upon stimulation in vitro with PMA/ionomycin compared to vehicle controls. Conclusion: In the context of lung cancer, MAIT cells are activated but may lose functionality within the tumor-immune microenvironment. Rationale: There is growing interest in the immunotherapeutic potential of unconventional T cells due to their rapid effector functions and non-MHC-restricted nature. By investigating the role of MAIT cells in the tumor microenvironment, we can comprehensively identify their biological advantages and limitations. Citation Format: Stephanie WY Wong, Carolina de Amat Herbozo, Adriana Vukosich-Pennell, Ben X Wang, Pamela S Ohashi, Adrian G Sacher. Characterizing MAIT cells in lung cancer: Insights from NSCLC and murine models [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr B030.

MAIT Cells: Partners or Enemies in Cancer Immunotherapy?

Revealing the protective and pathogenic potential of MAIT cells

Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential

MAIT Cells Modulate Innate Immune Cells and Inhibit Colon Cancer Growth

Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions

Abstract 6689: Modulation of MAITs by the tumor microbiome in anti-PD1 treated cancers

Mucosal‐associated invariant T cells modulate innate immune cells and inhibit colon cancer growth

Abstract B030: Characterizing MAIT cells in lung cancer: Insights from NSCLC and murine models

Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response

New insights into MAIT cells in autoimmune diseases.

MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations

Mining the multifunction of mucosal-associated invariant T cells in hematological malignancies and transplantation immunity: A promising hexagon soldier in immunomodulatory

Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy

MAIT cells and the microbiome

Circulating and Tumor-Infiltrating Mucosal Associated Invariant T (MAIT) Cells in Colorectal Cancer Patients.

Systematic analysis of mucosal‐associated invariant T cells in haematological malignancies

MAIT cells in bacterial infectious diseases: Heroes, villains, or both?

Mucosal‐associated invariant T cells in digestive tract: Local guardians or destroyers?

MAIT cell heterogeneity across paired human tissues reveals specialization of distinct regulatory and enhanced effector profiles

Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients

Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease